Syneron Candela acquires Danish medical device company Ellipse
Medical industry news : Syneron Candela, a US-based aesthetic device company, has announced the acquisition of Danish medical device company Ellipse for an undisclosed price.
The financial terms of Syneron Candela acquisition of Ellipse have not been disclosed.
Ellipse is engaged in manufacturing Intense Pulsed Light (IPL) and laser-based platforms for a range of medical and aesthetic skin treatments, that include skin rejuvenation, skin resurfacing, hair removal, and also for treatment of vascular and pigmented lesions.
Currently, the Danish medical device company sells its devices in about 50 countries.
Jacob Kildegaard Larsen – CEO of Ellipse, commenting on Syneron Candela acquisition of Ellipse, said: “We are excited to join forces with Syneron Candela and market our strong technology platforms via Syneron Candela’s expansive global footprint, along with its commitment to clinical excellence, quality and innovation.”
For the US aesthetic device company Syneron Candela, the acquisition of Ellipse enables it to consolidate its presence in the multi-application space apart from giving its customers a comprehensive portfolio.
One of the main products of Ellipse is Nordlys, which is used for vascular and pigmented lesions and also for hair removal. Apart from that, the other products of the Danish medical device company include an IPL-based system for skin rejuvenation, hair removal and facial veins, and a fractional nonablative laser system for skin resurfacing.
Commenting on Syneron Candela acquisition of Ellipse, Geoffrey Crouse – CEO of Syneron Candela, said: “Syneron Candela’s best-in-class laser and energy-based technologies are now coupled with a trusted IPL technology that is well respected by physicians.
“Ellipse platforms will provide aesthetic practices with a fully scalable multi-application, multi-technology device. We look forward to Ellipse strengthening our portfolio as we continue to deliver our brand promise of Science, Results, Trust to our physicians and patients worldwide. The Ellipse product portfolio is consistent with our commitment to scientifically proven technologies backed by consistent clinical outcomes.”